IP Library Granted Patent US 7,014,990
Granted Patent B2
US 7,014,990 · App. 09/976,805 · Granted Mar 21, 2006

Machine perfusion solution for organ and biological tissue preservation

Assignee: Ben O'Mar Arrington
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,014,990
App. No.
09/976,805
Granted
Mar 21, 2006
Kind
B2
Abstract

Machine perfusion solutions for the presentation of organs and biological tissues prior to implantation, including a prostaglandin having vasodilatory, membrane stabilizing, platelet aggregation prevention upon reperfusion, and complement activation inhibitory properties, a nitric oxide donor, a glutathione-forming agent, and an oxygen free radical scavenger.

Claims (62)

1. The machine perfusion solution of claim 1 wherein the solution comprises about 1,000 micrograms/L prostaglandin E1, about 10 mg/L nitroglycerin, and about 0.2 mg/L N-acetylcysteine, further comprising:

about 60–100 mM sodium gluconate;

about 20–30 mM KH 2 PO 4 ;

about 3–8 mM magnesium gluconate;

about 3–8 mM adenine;

about 3–8 mM ribose;

about 0.3–0.8 mM CaCl 2 ;

about 8–15 mM HEPES;

about 8–15 mM glucose;

about 15–50 mM mannitol; and

about 45–55 g/L pentastarch.

2. The machine perfusion solution of claim 1 wherein the solution comprises about 1,000 micrograms/L prostaglandin E1, about 10 mg/L nitroglycerin, and about 0.2 mg/L N-acetylcysteine, further comprising:

about 80 mM sodium gluconate;

about 25 mM KH 2 PO 4 ;

about 5 mM magnesium gluconate;

about 5 mM adenine;

about 5 mM ribose;

about 0.5 mM CaCl 2 ;

about 10 mM HEPES;

about 10 mM glucose;

about 30 mM mannitol; and

about 50 g/L pentastarch.

3. The machine perfusion solution of claim 1 or 2 further comprising at least one of distilled water and deionized water.

4. An organ or biological tissue preservation aqueous machine perfusion solution comprising:

about 1,000 micrograms/L prostaglandin E1;

about 10 mg/L nitroglycerin;

about 0.2 mg/L N-acetylcysteine;

about 40–160 mM sodium gluconate;

about 10–50 mM KH 2 PO 4 ;

about 1–15 mM magnesium gluconate;

about 1–15 mM adenine;

about 1–15 mM ribose;

about 0.1–2 mM CaCl 2 ;

about 1–30 mM HEPES;

about 1–30 mM glucose;

about 10–100 mM mannitol;

about 40–60 g/L pentastarch; and

about 700–900 mL sterile water.

5. A method for preserving a cadaveric organ or biological tissue, wherein the organ or tissue is a kidney or tissue from a kidney, comprising:

pouring the machine perfusion solution of claim 1 , 2 , 3 or 4 into a chamber that mimics at least one of a deep hypothermic environment and physiological environment;

circulating the machine perfusion solution continuously through the chamber;

inserting the at least one of a cadaveric organ and tissue into the chamber; and

flushing the at least one of a cadaveric organ and tissue with the machine perfusion solution.

6. The method of claim 5 wherein the flushing comprises:

infusing the solution through vasculature of the at least one of a cadaveric organ and tissue.

7. The method of claim 5 wherein the flushing comprises:

infusing the solution over or through an avascular biological substance of the at least one of a cadaveric organ and tissue to maintain viability during an ex vivo period.

8. The method of claim 5 further comprising:

monitoring parameters of the at least one of a cadaveric organ and tissue.

9. The method of claim 5 further comprising:

exsanguinating the at least one of a cadaveric organ and tissue; and

replacing the machine perfusion solution with at least blood to return the at least one of a cadaveric organ and tissue to a normothermic condition.

10. A method of preparing an organ or biological tissue preservation machine perfusion solution of claim 1 , 2 , 3 or 4 comprising:

providing a solution with sterile water;

adding the sodium gluconate, potassium phosphate, adenine, ribose, calcium chloride, pentastarch, magnesium gluconate, HEPES, glucose, mannitol, and insulin to the solution; and

mixing the prostaglandin E1, nitroglycerin and N-acetylcysteine into the solution.

11. The method of claim 10 further comprising:

mixing the solution until all components are dissolved.

12. The method of claim 10 further comprising:

infusing the pentastarch under pressure through a dialyzing filter;

centrifuging the prostaglandin E1 under hypothermic conditions; and

filtering the centrifuged prostaglandin E1.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2015
From: PROCENT TECHNOLOGIES, LLC
To: ORGAN RECOVERY SYSTEMS, INC.
Reel/Frame 035028/0767 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2006
From: ARRINGTON, BEN O'MAR
To: PROCENT TECHNOLOGIES, LLC
Reel/Frame 018597/0799 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2005
From: PIKE LABORATORIES, INC.
To: ARRINGTON, BEN O'MAR
Reel/Frame 015585/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2001
From: POLYAK, MAXIMILIAN; ARRINGTON, BEN O'MAR
To: PIKE LABORATORIES, INC.
Reel/Frame 012274/0540 →
Continuity (2)
Provisional Application 6024002400 · Oct 13, 2000
Related Publication 20020068268A1 · Jun 6, 2002